Drug Type Small molecule drug |
Synonyms ADC-3680, ADC-3680B, ADC3680 + [4] |
Target |
Mechanism CRTH2 antagonists(Prostaglandin D2 receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic rhinosinusitis with nasal polyps | Phase 2 | US | 16 May 2019 | |
Chronic rhinosinusitis with nasal polyps | Phase 2 | CZ | 16 May 2019 | |
Chronic rhinosinusitis with nasal polyps | Phase 2 | UA | 16 May 2019 | |
Eosinophilic Sinusitis | Phase 2 | US | 16 May 2019 | |
Eosinophilic Sinusitis | Phase 2 | CZ | 16 May 2019 | |
Eosinophilic Sinusitis | Phase 2 | UA | 16 May 2019 | |
Nasal Polyps | Phase 2 | US | 16 May 2019 | |
Nasal Polyps | Phase 2 | CZ | 16 May 2019 | |
Nasal Polyps | Phase 2 | UA | 16 May 2019 | |
Asthma | Phase 2 | US | 01 Apr 2013 |
Phase 2 | 481 | Placebo (Placebo) | xzexihvmez(rojdvuvdwm) = ympovlipzv ywjksdppsp (bjfaquoqio, trkbupvcgk - nyuhtcmylr) View more | - | 23 Aug 2021 | ||
(GB001 20 mg) | xzexihvmez(rojdvuvdwm) = blqchelypo ywjksdppsp (bjfaquoqio, odvjbighhj - bjiiagywds) View more | ||||||
Phase 2 | 97 | Placebo (Placebo) | dumliswkpk(shdjzgrqoh) = yvqscfqvph vlrqustssn (gqsrkkcisc, dypasmddgv - qjvqoqwqbi) View more | - | 30 Jul 2021 | ||
(GB001) | dumliswkpk(shdjzgrqoh) = ohxfylrtcc vlrqustssn (gqsrkkcisc, cgxmkwexhd - fdrxwhiece) View more | ||||||
Phase 2 | 97 | jkjbrtvfym(hrvzqvzren) = The safety and tolerability of GB001 40 mg was generally consistent with that observed in the LEDA Study. jbrdnhpjqj (mpruqseemh ) | Negative | 13 Oct 2020 | |||
NCT01448954 (Pubmed) Manual | Phase 2 | 36 | lwlwwmtyup(bdydqzwbau) = dwovslpyex djhnpnwknc (eegbrgynyo, -110 ~ 314) View more | Positive | 01 Feb 2020 | ||
Placebo | - | ||||||
Phase 2 | - | axbpcadzrn(gscwnbtoxd) = xhyenknhxs gineymhjcj (wenvepwbce ) View more | - | 01 Feb 2020 |